Plasma kinetics of an LDL-like nanoemulsion and lipid transfer to HDL in subjects with glucose intolerance

Abstract

OBJECTIVE:Glucose intolerance is frequently associated with an altered plasma lipid profile and increased cardiovascular disease risk. Nonetheless, lipid metabolism is scarcely studied in normolipidemic glucose-intolerant patients. The aim of this study was to investigate whether important lipid metabolic parameters, such as the kinetics of LDL free and esterified cholesterol and the transfer of lipids to HDL, are altered in glucose-intolerant patients with normal plasma lipids.METHODS:Fourteen glucose-intolerant patients and 15 control patients were studied; none of the patients had cardiovascular disease manifestations, and they were paired for age, sex, race and co-morbidities. A nanoemulsion resembling a LDL lipid composition (LDE) labeled with 14C-cholesteryl ester and 3H-free cholesterol was intravenously injected, and blood samples were collected over a 24-h period to determine the fractional clearance rate of the labels by compartmental analysis. The transfer of free and esterified cholesterol, triglycerides and phospholipids from the LDE to HDL was measured by the incubation of the LDE with plasma and radioactivity counting of the supernatant after chemical precipitation of non-HDL fractions.RESULTS:The levels of LDL, non-HDL and HDL cholesterol, triglycerides, apo A1 and apo B were equal in both groups. The 14C-esterified cholesterol fractional clearance rate was not different between glucose-intolerant and control patients, but the 3H-free- cholesterol fractional clearance rate was greater in glucose-intolerant patients than in control patients. The lipid transfer to HDL was equal in both groups.CONCLUSION:In these glucose-intolerant patients with normal plasma lipids, a faster removal of LDE free cholesterol was the only lipid metabolic alteration detected in our study. This finding suggests that the dissociation of free cholesterol from lipoprotein particles occurs in normolipidemic glucose intolerance and may participate in atherogenic signaling.

Receptor-Mediated Drug Delivery Systems Targeting to Glioma

“…Low density lipoprotein receptor (LDLR), which is able to prompt the internalization of lipoprotein, has been reported to be highly expressed on the BBB and glioma cells [ 29 , 65 ]. Moreover, some studies on the distribution of LDLR suggested that normal brain tissues, particularly neurons, have relatively low LDLR numbers [ 66 ].…”

Organic effects of associating paclitaxel with a lipid-based nanoparticle system on a nonhuman primate, <em>Cebus apella</em>

“…Chemotherapy in patients with diabetes requires precautions, since it has been demonstrated that some drugs can interfere with patients' blood-glucose levels, worsening the control of this disease. [44][45][46] Upon observing the results obtained in the plasmatic makeup of lipids, we found a significant difference in cholesterol levels in groups treated with LDE-PTX in relation to those of the NC. These levels, however, were within the normal range for the species C. apella, which is between 62.0 and 223.0 mg/dL.…”

Nanoemulsion delivery systems for enhanced efficacy of antimicrobials and essential oils

“…NE have found many applications in therapies targeting other medical ailments such as cancer, ocular diseases, hypertension, and diabetes. 94,95,104–111 Although many research groups have accomplished the formulation of blank or drug-loaded NE that exhibit antimicrobial, antifungal, or antiviral effects, the clinical translation of NE thus far for anti-infective purposes has been limited. Only a few antimicrobial NE therapies have gone from preclinical to clinical testing in recent years.…”